Revenue segments as reported by the company.

Protein Sciences

Diagnostics and Genomics

lntersegment

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bio-Techne

Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the following segments: Protein Sciences and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures purified proteins and reagent solutions most notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies. This segment also includes protein analysis solutions that offer researchers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. The Diagnostics & Genomics segment develops and manufactures diagnostic products, including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx Prostate (IntelliScore) test (EPI) for prostate cancer diagnosis. This segment also manufactures and sells advanced tissue-based in-situ hybridization assays (ISH) for research and clinical use. The company was founded in 1976 and is headquartered in Minneapolis, MN.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Bio-Techne Corp reports steady Q3 revenue growth amidst China challenges

Bio-Techne Corp reported steady Q3 revenue growth despite challenges in China and temporary headwinds. The company is focused on driving growth in strategic platforms and expanding key franchises. Succession planning and margin improvement are key areas of focus for future growth.

Bio-Techne reports strong Q2 earnings, eyes growth in diagnostics

Bio-Techne's Q2 2023 earnings call highlighted solid performance, strategic strengths in key segments, challenges in ordering patterns, and growth opportunities in diagnostics and research.
The company's focus on innovation, cost management, and strategic investments positions it well for future growth and reaching ambitious revenue targets by FY 2026.
Despite short-term challenges in certain markets, Bio-Techne remains optimistic about its long-term growth prospects and transparent communication with investors.
With a strong financial performance, expanding product portfolio, and a focus on high-growth areas, Bio-Techne is poised for sustained success and market leadership.

Bio-Techne reports solid Q3 performance, eyes growth in key segments

Bio-Techne's Q3 performance showcased strengths in key segments like ExoDx Prostate test demand and GMP proteins, despite challenges in certain markets and OEM destocking dynamics. The company's strategic focus on expanding the Wilson Wolf franchise and driving growth in ACD and key segments like cell and gene therapy position it well for future success. Addressing challenges and capitalizing on growth opportunities will be pivotal for Bio-Techne's continued expansion and market leadership.

Bio-Techne (TECH) excels in Q4, eyes growth amid challenges

Bio-Techne (TECH) reports strong revenue growth and promising future prospects.
Strategic focus on key segments like cell and gene therapy and spatial biology.
Challenges in macroenvironment and funding uncertainties require cautious navigation.
Active M&A strategy and investments to drive growth and market dominance.

Bio-Techne reports steady Q1 growth amid industry challenges

Bio-Techne's Q1 performance showed resilience amidst industry challenges, with a focus on key growth areas and regions. While facing headwinds, the company remains cautiously optimistic about future prospects, emphasizing long-term growth opportunities and productivity measures.

Bio-Techne reports Q2 revenue growth amidst China challenges and opportunities

Bio-Techne's Q2 performance reflects revenue growth and operational efficiency, despite challenges.
Strengths lie in core businesses, Diagnostics and Genomics growth, and record consumables usage in China.
Challenges include market declines, funding constraints, and headwinds in biopharma and academic markets.
Opportunities exist in market normalization, China growth, new product releases, and M&A strategies.

Bio-Techne surpasses Q3 expectations, eyes growth in emerging markets

Bio-Techne's Q3 showcased strong financial performance, with revenue growth and margin expansion across key segments, setting the stage for continued success.
The company's focus on innovation, awards recognition, and strategic market positioning in high-growth areas like cell and gene therapy underpin its competitive strength.
While facing challenges in certain regions and production constraints, Bio-Techne's proactive approach to scaling up manufacturing and diversifying markets positions it well for future growth.
With a clear emphasis on operational efficiency, market expansion, and strategic investments, Bio-Techne is poised for sustained success and value creation for stakeholders.

Bio-Techne reports solid Q4 performance and eyes market recovery

Bio-Techne's Q4 2024 performance reflects resilience and potential for accelerated growth as markets recover in fiscal year 2025.
Strategic leadership additions, productivity initiatives, and market recovery expectations position the company for future success.
Challenges such as capacity constraints and funding environments require strategic management for sustained growth.
Opportunities lie in market recovery, margin improvement, and growth prospects across different segments for Bio-Techne in the coming year.

Bio-Techne reports solid Q1 earnings, eyes growth in biotech markets

Bio-Techne (TECH) delivered solid Q1 2025 results with organic revenue growth, strong segment performances, and a focus on sustainability and strategic partnerships.
While facing challenges in certain markets, the company's emphasis on cost containment and productivity optimization bodes well for future profitability and resilience.
With a positive outlook for growth and opportunities in key segments, Bio-Techne is poised for continued success and market leadership in the biotech industry.
Investors can be optimistic about Bio-Techne's performance, strategic initiatives, and growth prospects, supported by a strong financial foundation and market positioning.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bio-Techne Corp. is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. It operates through the Protein Sciences, and Diagnostics and Genomics segments. The Protein Sciences segment develops and manufactures purified proteins, and reagent solutions. The Diagnostics and Genomics segment develops and manufactures diagnostic products. The company was founded in 1976 and is headquartered in Minneapolis, MN.

MINNEAPOLIS , March 15, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it has completed its participation in the Cell and Gene Therapy Catapult Process Analytical Technology (Catapult PAT) consortium, a multi-year collaboration involving 24 partner companies, technology providers, therapy developers, and charities. The Catapult PAT consortium is the first initiative of this scale and functional expertise with member companies and organizations collaborating to develop cell and gene therapy-specific process analytical technologies.

BIO-TECHNE ANNOUNCES COMPLETION OF CELL AND GENE THERAPY CATAPULT PROCESS ANALYTICAL TECHNOLOGY (PAT) CONSORTIUM

MINNEAPOLIS , March 10, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Jim Hippel, Executive Vice President and Chief Financial Officer, will present at the Barclays Global Healthcare Conference on Tuesday, March 14, 2023, at 2:35 p.m. EDT. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.

BIO-TECHNE TO PRESENT AT THE BARCLAYS GLOBAL HEALTHCARE CONFERENCE

MINNEAPOLIS , March 1, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced Wilson Wolf Manufacturing has met the trailing 12-month earnings before interest, taxes, depreciation, and amortization (EBITDA) target of $55 million, triggering Bio-Techne's initial investment in the company, which is expected to close at the end of March 2023. Bio-Techne's $257 million investment will give the Company a 20% ownership stake in Wilson Wolf.

BIO-TECHNE ANNOUNCES INVESTMENT IN WILSON WOLF

MINNEAPOLIS , Feb. 28, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the Cowen 43rd Annual Health Care Conference on Monday, March 6, 2023, at 2:10 p.m. EST. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.

BIO-TECHNE TO PRESENT AT THE COWEN 43rd ANNUAL HEALTH CARE CONFERENCE

Medicare contractor National Government Services finalizes local coverage determination for biomarker testing related to prostate cancer to include repeat biopsies and yearly testing MINNEAPOLIS , Feb. 24, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that a newly finalized local coverage determination (LCD) from National Government Services, Inc., a Medicare Administrative Contractor, includes coverage for the ExoDx™ Prostate Test from Exosome Diagnostics, a Bio-Techne brand. The updated policy now covers an annual ExoDx Prostate Test for men who already had a negative biopsy but are thought to be at high risk for prostate cancer and are considering a repeat biopsy.

ExoDx PROSTATE TEST GRANTED EXPANDED COVERAGE BY MEDICARE

MINNEAPOLIS , Feb. 22, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Jim Hippel, Executive Vice President and Chief Financial Officer, will present at the Citi 2023 Healthcare Services, Medtech, Tools & HCIT Conference on Wednesday, March 1, 2023, at 2:00 p.m. EST. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.

BIO-TECHNE TO PRESENT AT THE CITI 2023 HEALTHCARE SERVICES, MEDTECH, TOOLS & HCIT CONFERENCE

MINNEAPOLIS , Feb. 14, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) and Cell Signaling Technology ( CST ) announced today the addition of Simple Western™ validation to CST antibodies. This will allow researchers in various disciplines an easier way to study important molecular signaling pathways on a trusted and validated platform.

BIO-TECHNE AND CELL SIGNALING TECHNOLOGY ANNOUNCE PARTNERSHIP TO VALIDATE SIMPLE WESTERN ANTIBODIES

Bio-Techne Corporation (NASDAQ:TECH ) Q2 2023 Earnings Conference Call February 2, 2023 9:00 AM ET Company Participants David Clair - Vice President of Investor Relations Chuck Kummeth - Chief Executive Officer Jim Hippel - Chief Financial Officer Conference Call Participants Puneet Souda - SVB Securities Jacob Johnson - Stephens Dan Arias - Stifel Dan Leonard - Credit Suisse Catherine Schulte - Baird Patrick Donnelly - Citi Justin Bowers - Deutsche Bank Operator Good morning, and welcome to the Bio-Techne Earnings Conference Call for the Second Quarter of Fiscal Year 2023. At this time, all participants have been placed in a listen-only mode, and the call will be open for questions following management's prepared remarks.

Bio-Techne Corporation (TECH) Q2 2023 Earnings Call Transcript

Techne (TECH) delivered earnings and revenue surprises of -4.08% and 6.34%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Techne (TECH) Q2 Earnings and Revenues Miss Estimates

MINNEAPOLIS , Feb. 2, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the second quarter ended December 31, 2022. Second Quarter FY2023 Highlights Second quarter organic revenue increased by 4% (1% reported) to $271.6 million and 5% (3% reported) in the first half of fiscal 2023 to $541.2 million.

BIO-TECHNE RELEASES SECOND QUARTER FISCAL 2023 RESULTS

MINNEAPOLIS , Jan. 31, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced Shane Bohnen has been appointed Senior Vice President, General Counsel effective March 3, 2023.  Mr. Bohnen succeeds Brenda Furlow, who will be retiring from the Company after serving as Executive Vice President and General Counsel for the past nine years.

BIO-TECHNE ANNOUNCES RETIREMENT, APPOINTMENT OF GENERAL COUNSEL

AbbVie

Fate Therapeutics

1Life Healthcare

Third Harmonic Bio Inc

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

5 Cheapest Health Care Stocks You Should Think About

Techne (TECH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Techne (TECH) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

MINNEAPOLIS , Jan. 26, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced the launch of its ProteinSimple-branded MauriceFlex™ during the WCBP conference in Washington D.C. MauriceFlex™ enables protein charge variant fractionation plus routine cIEF & CE-SDS assays, making it a unique multi-functional system that further streamlines protein characterization workflows.

BIO-TECHNE LAUNCHES THE MauriceFlex™ SYSTEM, ADDING cIEF FRACTIONATION CAPABILITY TO THE GOLD STANDARD MAURICE ASSAYS

Century Therapeutics

Novo Integrated Sciences, Inc.

Synaptogenix

5 Health Care Stocks That Are Diving - And May Rally

MINNEAPOLIS, Jan. 17, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Thursday, February 2, 2023, at 8:00 a.m. CST to review second quarter 2023 financial results.

BIO-TECHNE TO HOST CONFERENCE CALL ON FEBRUARY 2, 2023, TO ANNOUNCE SECOND QUARTER 2023 FINANCIAL RESULTS

Regeneron Pharmaceuticals

REGN vs. TECH: Which Stock Is the Better Value Option?

REGN or TECH: Which Is the Better Value Stock Right Now?

An integrated assay using proprietary RNAscope ™ and miRNAscope ™ technologies to measure the biodistribution and function of novel gene therapies and endogenous regulatory RNAs. MINNEAPOLIS , Jan. 10, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced the expansion of its Advanced Cell Diagnostics (ACD)-branded RNAscope™ in situ hybridization (ISH) portfolio with the release of the RNAscope Plus smRNA-RNA detection assay.

BIO-TECHNE LAUNCHES RNASCOPE PLUS ASSAY TO ADVANCE GENE THERAPY DEVELOPMENT

MINNEAPOLIS , Dec. 21, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023, at 8:15 a.m.

BIO-TECHNE TO PRESENT AT THE 41st ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

Corcept Therapeutics

Genmab - ADR

Novo Nordisk

United Therapeutics

Vertex Pharmaceuticals

If there's a silver lining regarding the coronavirus pandemic, it's that it demonstrated the importance of the top biotech stock picks for 2023. While medical innovations may seem frustratingly slow, the Covid-19 crisis proved that when humanity comes together, it can foster incredible advancements at breakneck speed.

Our 7 Top Biotech Stock Picks for 2023

Biogen

BIIB vs. TECH: Which Stock Is the Better Value Option?

MINNEAPOLIS, Dec. 5, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced the introduction of MitoBrilliant™ probes.  These novel probes enable the fluorescent labeling and tracking of mitochondria in live and fixed cells.

BIO-TECHNE RELEASES MITOBRILLIANT™ FLUORESCENT DYES, PROVIDING A NEXT-GENERATION TOOL FOR IMAGING MITOCHONDRIA IN LIVE AND FIXED CELLS

New collaboration will develop assays that offer a streamlined workflow for analysing even the most challenging genes. MINNEAPOLIS , Dec. 1, 2022 /PRNewswire/ -- Asuragen, a Bio-Techne brand (NASDAQ: TECH) and Oxford Nanopore Technologies plc (Oxford Nanopore) (LSE: ONT), today announce a collaboration to develop assays designed to deliver more accurate and reliable options for reproductive health and carrier screening.

Bio-Techne and Oxford Nanopore Technologies partner to bring innovative reproductive health and carrier screening solutions to the market

MINNEAPOLIS , Nov. 28, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the Fifth Annual Evercore ISI HealthCONx Conference on Tuesday, November 29, 2022, at 8:50 a.m. EST. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.

BIO-TECHNE TO PRESENT AT THE FIFTH ANNUAL EVERCORE ISI HealthCONx CONFERENCE

VRTX vs. TECH: Which Stock Is the Better Value Option?

News for Bio-Techne Stock (TECH)